Cell cycle, CDKs and cancer: a changing paradigm

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Tumourigenesis is frequently linked to cell cycle dysregulation, often involving altered cyclin-dependent kinase (CDK) activity.
• Misregulated CDKs contribute to uncontrolled cell proliferation and genomic instability, hallmarks of cancer.
• Current understanding posits that mammalian CDKs are indispensable for all cell cycle phases, limiting the therapeutic potential of CDK inhibitors against cancer.

Purpose of the Study:

• To investigate the essentiality of specific interphase cyclin-dependent kinases (CDKs) in tumour cell proliferation.
• To evaluate the potential of selective CDK inhibition as a targeted cancer therapy.

Main Methods:

• Analysis of recent genetic evidence regarding CDK roles in cell cycle progression.
• Exploration of emerging data on tumour cell dependency on specific interphase CDKs.

Main Results:

• CDK1 is essential for the overall cell cycle.
• Interphase CDKs, unlike CDK1, are primarily essential for the proliferation of specialized cell types.
• Emerging evidence indicates that tumour cells may depend on particular interphase CDKs for their proliferation.

Conclusions:

• Selective inhibition of specific interphase CDKs, rather than broad CDK inhibition, may offer a targeted therapeutic strategy.
• Targeted CDK inhibition holds promise for treating certain human neoplasias by exploiting tumour-specific dependencies.